After declining in 2016, share price of French pharma giant Sanofi SNY has picked up in 2017. This Zacks Rank #2 (Buy) stock has risen 21.1% this year so far, outperforming the return of the Zacks classified Large-Cap Pharma industry of …
This deal represents a noteworthy 64% premium compared to where Bioverativ's shares closed last Friday. Sanofi stock is down by 2.85% in pre-market trading, while Biogen's is up by 1.37% on the back of this news. Sanofi has been …
Strengthens Sanofi's R & D strategy with innovative Nanobody® technology platform Expands growing rare blood disorders franchise with Ablynx's late-stage investigational caplacizumab aTTP treatment Unanimously approved by Sanofi and …
French drug giant Sanofi SA (SNYNF,SNY) Monday announced an agreement to buy US-based hemophilia drugmaker Bioverativ Inc. (BIVV) for around $11.6 billion. The deal expands Sanofi's presence in specialty care and strengthens …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
In keeping with the commitment to dynamically provide members with timely information WallStEquities.com has issued …
X Workday's impressive list of clients doesn't stop there, with Hewlett Packard Enterprise (HPE), Sanofi (SNY) and even Rolls-Royce also ... Netflix and BofA is …
Sanofi traded about 4% lower to $42.72 a share. The stock has a 52-week range of $39.42 to $50.65 and a consensus price target of $49.50.
Expands growing rare blood disorders franchise with Ablynx's late-stage investigational caplacizumab aTTP treatment Unanimously approved by Sanofi and Ablynx Boards of Directors Paris, France and Ghent, Belgium - January 29, 2018 …
Eyelea U.S. sales and sales of Praluent and Dupixent, two collaborations between Regeneron and Sanofi SNY, -4.08% beat the FactSet consensus. Arcalyst sales matched the consensus and sales of Kevzara and Zaltrap, which are also …